Metabolomics changes after rTMS intervention reveal potential peripheral biomarkers in methamphetamine dependence

2022 ◽  
Vol 56 ◽  
pp. 80-88
Author(s):  
Hang Su ◽  
Pingyuan Yang ◽  
Tianzhen Chen ◽  
Di Deng ◽  
Na Zhong ◽  
...  
Keyword(s):  
Methamphetamine Dependence

scholarly journals Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e044696
Author(s):  
Nadine Ezard ◽  
Brendan Clifford ◽  
Adrian Dunlop ◽  
Raimondo Bruno ◽  
Andrew Carr ◽  
...  
Keyword(s):  
Adverse Events ◽  
Risk Behaviour ◽  
Phase 2 ◽  
Open Label ◽  
Dose Escalation Study ◽  
Stimulant Use ◽  
Treatment Services ◽  
Drug Tolerability ◽  
Methamphetamine Dependence ◽  
Icd 10

ObjectivesTo examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at 250 mg/day among adults with methamphetamine (MA) dependence.DesignA dose-escalating, phase-2, open-label, single-group study of oral LDX at two Australian drug treatment services.SettingThe study was conducted at two Australian stimulant use disorder treatment clinics.ParticipantsThere were 16 participants: at least 18 years old, MA dependent for at least the preceding 2 years using ICD-10 criteria, reporting use of MA on at least 14 of the preceding 28 days.InterventionsDaily, supervised LDX of 100–250 mg, single-blinded to dose, ascending-descending regimen over 8 weeks (100–250 mg over 4 weeks; followed by 4-week dose reduction regimen, 250–100 mg). Participants were followed through to week 12.OutcomesPrimary outcomes were safety, drug tolerability and regimen completion at the end of week 4. Participants were followed to week 12. Secondary outcomes included: change in MA use; craving; withdrawal; severity of dependence; risk behaviour; change in other substance use; medication acceptability; potential for non-prescription use; adherence and neurocognitive functioning.ResultsFourteen of 16 participants (87.5%) completed escalation to 250 mg/day. Two participants withdrew from the trial in the first week: one relocated away from the study site, the other self-withdrew due to a possible, known side effect of LDX (agitation). There was one serious adverse event of suicidal ideation which resolved. All other adverse events were mild or moderate in severity and known side effects of LDX. No participant was withdrawn due to adverse events. MA use decreased from a median of 21 days (IQR: 16–23) to 13 days (IQR: 11–17) over the 4-week escalation period (p=0.013).ConclusionsLDX at a dose of up to 250 mg/day was safe and well tolerated by study participants, warranting larger trials as a pharmacotherapy for MA dependence.Trial registration numberACTRN12615000391572.

P.6.c.006 Association between the tyrosine hydroxylase gene and patients with methamphetamine dependence

2012 ◽  
Vol 22 ◽  
pp. S401-S402
Author(s):  
Y. Okahisa ◽  
M. Kishimoto ◽  
S. Sakamoto ◽  
Y. Mizuki ◽  
M. Takaki ◽  
...  
Keyword(s):  
Tyrosine Hydroxylase ◽  
Tyrosine Hydroxylase Gene ◽  
Hydroxylase Gene ◽  
Methamphetamine Dependence

scholarly journals Childhood maltreatment and amygdala connectivity in methamphetamine dependence: a pilot study

2014 ◽  
Vol 4 (6) ◽  
pp. 867-876 ◽  
Author(s):  
Andy C. Dean ◽  
Milky Kohno ◽  
Gerhard Hellemann ◽  
Edythe D. London
Keyword(s):  
Pilot Study ◽  
Childhood Maltreatment ◽  
Methamphetamine Dependence

Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence

2006 ◽  
Vol 85 (1) ◽  
pp. 12-18 ◽  
Author(s):  
Steven Shoptaw ◽  
Alice Huber ◽  
James Peck ◽  
Xiaowei Yang ◽  
Juanmei Liu ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Contingency Management ◽  
Methamphetamine Dependence

scholarly journals Gray-matter volume in methamphetamine dependence: Cigarette smoking and changes with abstinence from methamphetamine

2012 ◽  
Vol 125 (3) ◽  
pp. 230-238 ◽  
Author(s):  
Angelica M. Morales ◽  
Buyean Lee ◽  
Gerhard Hellemann ◽  
Joseph O’Neill ◽  
Edythe D. London
Keyword(s):  
Cigarette Smoking ◽  
Gray Matter ◽  
Gray Matter Volume ◽  
Matter Volume ◽  
Methamphetamine Dependence

scholarly journals Changes in psychiatric symptoms among persons with methamphetamine dependence predicts changes in severity of drug problems but not frequency of use

2015 ◽  
Vol 37 (1) ◽  
pp. 209-214 ◽  
Author(s):  
Douglas L. Polcin ◽  
Rachael Korcha ◽  
Jason Bond ◽  
Gantt Galloway ◽  
Madhabika Nayak
Keyword(s):  
Psychiatric Symptoms ◽  
Methamphetamine Dependence ◽  
Frequency Of Use ◽  
Drug Problems

Varenicline for the treatment of methamphetamine dependence

2015 ◽  
Vol 156 ◽  
pp. e28
Author(s):  
Marisa Briones ◽  
Matthew Worley ◽  
Dustin DeYoung ◽  
Aimee-Noelle Swanson ◽  
Keith G. Heinzerling ◽  
...  
Keyword(s):  
Methamphetamine Dependence
Sign in / Sign up

Export Citation Format

Share Document